In vitro and in silico approaches manifest the anti-leishmanial activity of wild edible mushroom .

Visceral Leishmaniasis, caused by is the second most deadly parasitic disease, causing over 65,000 deaths annually. Synthetic drugs available in the market, to combat this disease, have numerous side effects. In this backdrop, we aim to find safer antileishmanial alternatives with minimal side effects from mushrooms, which harbour various secondary metabolites with promising efficacy.

bark extract induces oxidative stress mediated cellular apoptosis in parasite modulated by its active phytosterol constituent.

Visceral leishmaniasis still remains a leading cause of parasitic deaths, with modern pentavalent antimonials showing limited efficacy and health risks. The methanolic bark extract of the Northeastern Indian plant, , demonstrated potent leishmanicidal effects against the parasite , demonstrating IC values of 20-36 µg/ml, with selective toxicity for parasites over healthy cells. It induced parasite death through elevated oxidative and nitrosative stress elements, reduced arginase activity, nuclear fragmentation, cell cycle arrest, and apoptosis.

Computational and experimental approaches manifest the leishmanicidal potential of α-mangostin resourced from Garcinia cowa.

Owing to the persistent number of parasitic deaths, Visceral leishmaniasis continues to haunt several economically weaker sections of India. The disease causes over 30,000 deaths and threatens millions annually on a global scale. The standard pentavalent antimonials, on the other hand, are associated with health adversities and disease relapse.

Accelerated Closure of Diabetic Wounds by Efficient Recruitment of Fibroblasts upon Inhibiting a 14-3-3/ROCK Regulatory Axis.

Chronic non-healing wounds negatively impact quality of life and are a significant financial drain on health systems. The risk of infection that exacerbates comorbidities in patients necessitates regular application of wound care. Understanding the mechanisms underlying impaired wound healing are therefore a key priority to inform effective new-generation treatments.

Evaluation of safety and early efficacy of AAV gene therapy in mouse models of vanishing white matter disease.

Leukoencephalopathy with vanishing white matter (VWM) is a progressive incurable white matter disease that most commonly occurs in childhood and presents with ataxia, spasticity, neurological degeneration, seizures, and premature death. A distinctive feature is episodes of rapid neurological deterioration provoked by stressors such as infection, seizures, or trauma. VWM is caused by autosomal recessive mutations in one of five genes that encode the eukaryotic initiation factor 2B complex, which is necessary for protein translation and regulation of the integrated stress response.